Multi-colour FISH in Oesophageal Adenocarcinoma-predictors of Prognosis Independent of Stage and Grade

Overview

Journal Br J Cancer

Specialty Oncology

Date 2014 May 24

PMID 24853183

Citations 8

Authors

C-I Geppert

P Rummele

M Sarbia

R Langer

M Feith

L Morrison

E Pestova

R Schneider-Stock

A Hartmann

T T Rau

Affiliations

Soon will be listed here.

Abstract

Background: Oesophageal adenocarcinoma or Barrett's adenocarcinoma (EAC) is increasing in incidence and stratification of prognosis might improve disease management. Multi-colour fluorescence in situ hybridisation (FISH) investigating ERBB2, MYC, CDKN2A and ZNF217 has recently shown promising results for the diagnosis of dysplasia and cancer using cytological samples.

Methods: To identify markers of prognosis we targeted four selected gene loci using multi-colour FISH applied to a tissue microarray containing 130 EAC samples. Prognostic predictors (P1, P2, P3) based on genomic copy numbers of the four loci were statistically assessed to stratify patients according to overall survival in combination with clinical data.

Results: The best stratification into favourable and unfavourable prognoses was shown by P1, percentage of cells with less than two ZNF217 signals; P2, percentage of cells with fewer ERBB2- than ZNF217 signals; and P3, overall ratio of ERBB2-/ZNF217 signals. Median survival times for P1 were 32 vs 73 months, 28 vs 73 months for P2; and 27 vs 65 months for P3. Regarding each tumour grade P2 subdivided patients into distinct prognostic groups independently within each grade, with different median survival times of at least 35 months.

Conclusions: Cell signal number of the ERBB2 and ZNF217 loci showed independence from tumour stage and differentiation grade. The prognostic value of multi-colour FISH-assays is applicable to EAC and is superior to single markers.

Citing Articles

Molecular Biomarkers Detected Using Fluorescence in situ Hybridization in a Filipino with Retinoblastoma.

Barzaga A, Perias G, Reyes L, Moreno P, Relacion P, Manalo R Acta Med Philipp. 2024; 58(10):99-107.

PMID: 38939426 PMC: 11199350. DOI: 10.47895/amp.vi0.7666.

ZNF217: An Oncogenic Transcription Factor and Potential Therapeutic Target for Multiple Human Cancers.

Wang Y, Ma C, Yang X, Gao J, Sun Z Cancer Manag Res. 2024; 16:49-62.

PMID: 38259608 PMC: 10802126. DOI: 10.2147/CMAR.S431135.

Novel Criteria for Intratumoral Budding with Prognostic Relevance for Colon Cancer and Its Histological Subtypes.

Pour Farid P, Eckstein M, Merkel S, Grutzmann R, Hartmann A, Bruns V Int J Mol Sci. 2021; 22(23).

PMID: 34884913 PMC: 8658236. DOI: 10.3390/ijms222313108.

ZNF217: the cerberus who fails to guard the gateway to lethal malignancy.

Li Y, Wu H, Wang Q, Xu S Am J Cancer Res. 2021; 11(7):3378-3405.

PMID: 34354851 PMC: 8332857.

Somatic deletion of gene is associated to advanced colorectal cancer stages.

Ramirez-Ramirez R, Gutierrez-Angulo M, Peregrina-Sandoval J, Moreno-Ortiz J, Franco-Topete R, Cerda-Camacho F J Clin Pathol. 2019; 73(2):107-111.

PMID: 31471467 PMC: 7027028. DOI: 10.1136/jclinpath-2019-206128.

References

Braun M, Kirsten R, Rupp N, Moch H, Fend F, Wernert N . Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histol Histopathol. 2013; 28(5):605-10. DOI: 10.14670/HH-28.605. View

Peitz U, Malfertheiner P . [Barrett carcinoma--diagnosis, screening, surveillance, endoscopic treatment, prevention]. Z Gastroenterol. 2007; 45(12):1264-72. DOI: 10.1055/s-2007-963638. View

Yao H, He S, Wu Y, Wang X, Han Y, Xu X . [Application of multicolor fluorescence in situ hybridization to early diagnosis of esophageal squamous cell carcinoma]. Ai Zheng. 2008; 27(11):1137-43. View

Rahman M, Nakayama K, Rahman M, Nakayama N, Ishikawa M, Katagiri A . Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer. 2011; 118(11):2846-57. DOI: 10.1002/cncr.26598. View

Albrecht B, Hausmann M, Zitzelsberger H, Stein H, Siewert J, Hopt U . Array-based comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma. J Pathol. 2004; 203(3):780-8. DOI: 10.1002/path.1576. View

Devesa S, Blot W, Fraumeni Jr J . Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998; 83(10):2049-53. View

Spechler S . Clinical practice. Barrett's Esophagus. N Engl J Med. 2002; 346(11):836-42. DOI: 10.1056/NEJMcp012118. View

Nielsen K, Ejlertsen B, Moller S, Jensen M, Balslev E, Muller S . Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. Mol Oncol. 2011; 6(1):88-97. PMC: 5528381. DOI: 10.1016/j.molonc.2011.11.006. View

Ruschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G . HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010; 457(3):299-307. PMC: 2933810. DOI: 10.1007/s00428-010-0952-2. View

10.

Reid B . Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am. 1991; 20(4):817-34. View

11.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

12.

Haggitt R . Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 1994; 25(10):982-93. DOI: 10.1016/0046-8177(94)90057-4. View

13.

Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C . Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens. Diagn Pathol. 2013; 8:17. PMC: 3584735. DOI: 10.1186/1746-1596-8-17. View

14.

Hamilton S, Smith R . The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol. 1987; 87(3):301-12. DOI: 10.1093/ajcp/87.3.301. View

15.

Barrett M, Sanchez C, Prevo L, Wong D, Galipeau P, Paulson T . Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet. 1999; 22(1):106-9. PMC: 1559997. DOI: 10.1038/8816. View

16.

Bubendorf L, Nocito A, Moch H, Sauter G . Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol. 2001; 195(1):72-9. DOI: 10.1002/path.893. View

17.

Igaki H, Sasaki H, Kishi T, Sakamoto H, Tachimori Y, Kato H . Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem Biophys Res Commun. 1994; 203(2):1090-5. DOI: 10.1006/bbrc.1994.2294. View

18.

Dobson L, Conway C, Hanley A, Johnson A, Costello S, OGrady A . Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation. Histopathology. 2010; 57(1):27-38. PMC: 2916223. DOI: 10.1111/j.1365-2559.2010.03577.x. View

19.

. Barrett's esophagus: epidemiological and clinical results of a multicentric survey. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago (GOSPE). Int J Cancer. 1991; 48(3):364-8. View

20.

Heitmiller R, Sharma R . Comparison of prevalence and resection rates in patients with esophageal squamous cell carcinoma and adenocarcinoma. J Thorac Cardiovasc Surg. 1996; 112(1):130-6. DOI: 10.1016/s0022-5223(96)70187-3. View